Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 16/20 | 0.88 |
| ▸ | BMPR1A | P36894 | 16/20 | 0.88 |
| ▸ | ACVRL1 | P37023 | 16/20 | 0.88 |
| ▸ | ACVR1 | Q04771 | 16/20 | 0.88 |
| ▸ | TGFBR1 | P36897 | 15/20 | 0.75 |
| ▸ | MERTK | Q12866 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19806978 | 0.94 | BMPR1B (1.00) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL29370244 | 0.94 | BMPR1B (1.00) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL19806979 | 0.94 | BMPR1B (1.00) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL19807056 | 0.86 | BMPR1B (1.00) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL29370385 | 0.86 | BMPR1B (1.00) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL24318078 | 0.77 | BMPR1B (0.77) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL19806976 | 0.77 | BMPR1B (0.77) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL20067750 | 0.76 | BMPR1B (0.68) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL20067749 | 0.76 | BMPR1B (0.68) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL18615504 | 0.76 | BMPR1B (0.68) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4442317-A2 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2024-10-09 | — | — | EP | disclosed |
| CN-114014844-B | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-3971177-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| EP-3971177-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-114014844-A | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR1, ACVR1B | BMPR1B 31/4885BMPR1A 61/4885ACVRL1 6/4885 |
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR1, ACVR1B | BMPR1B 34/4885BMPR1A 40/4885ACVRL1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.